-
explain the reasons why patients with T2D, CKD and hypertension are at higher risk of developing hyperkalemia.
-
describe the risks and benefits of the potassium binders.
-
choose which patients may benefit from continuing RAS and MRA therapy despite the risk of hyperkalemia.
About This Course
This course has been designed to teach healthcare professionals about how to manage the risk of hyperkalemia in patients with diabetes and chronic kidney disease. Patients with these concurrent diseases are at high risk of developing hyperkalemia, and it can be a life-threatening condition. This course provides clinicians with the tools they need to both delay the onset of and manage elevated potassium levels. Elements discussed include: SGLT2 inhibitors, RAAS inhibitors including non-steroidal MRAs, low-potassium diets, and potassium binders.
This course has been approved for AMA PRA Category 1 Credit(s)TM / 1 ANCC Contact Hour(s).
In order to claim the above credits, you must complete the course on the myCME website. Follow this link to complete the course on the myCME website: Hyperkalemia: The Achilles' Heel of Treatment for DKD | myCME
Learning Objectives
At the end of this course, students will be able to:
Course curriculum
-
-
Navigation Instructions
-
How to claim ANCC / AMA PRA credits
-
A Little Bit About You
-
Introduction to the Course
-
Precourse Quiz
-
Module 1
-
Module 2
-
Module 3
-
Course Summary
-
Postcourse Quiz
-

About this course
- Free
- 10 lessons
- 0 hours of video content
